The Prevalence and Cost of Unapproved Uses of Top-Selling Orphan Drugs

DSpace/Manakin Repository

The Prevalence and Cost of Unapproved Uses of Top-Selling Orphan Drugs

Citable link to this page

. . . . . .

Title: The Prevalence and Cost of Unapproved Uses of Top-Selling Orphan Drugs
Author: Winkelmayer, Wolfgang C.; Levin, Raisa; Kesselheim, Aaron Seth; Myers, Jessica Amelia; Solomon, Daniel Hal; Avorn, Jerry

Note: Order does not necessarily reflect citation order of authors.

Citation: Kesselheim, Aaron S., Jessica A. Myers, Daniel H. Solomon, Wolfgang C. Winkelmayer, Raisa Levin, and Jerry Avorn. 2012. The prevalence and cost of unapproved uses of top-selling orphan drugs. PLoS ONE 7(2): e31894.
Full Text & Related Files:
Abstract: Introduction: The Orphan Drug Act encourages drug development for rare conditions. However, some orphan drugs become top sellers for unclear reasons. We sought to evaluate the extent and cost of approved and unapproved uses of orphan drugs with the highest unit sales. Methods We assessed prescription patterns for four top-selling orphan drugs: lidocaine patch (Lidoderm) approved for post-herpetic neuralgia, modafinil (Provigil) approved for narcolepsy, cinacalcet (Sensipar) approved for hypercalcemia of parathyroid carcinoma, and imatinib (Gleevec) approved for chronic myelogenous leukemia and gastrointestinal stromal tumor. We pooled patient-specific diagnosis and prescription data from two large US state pharmaceutical benefit programs for the elderly. We analyzed the number of new and total patients using each drug and patterns of reimbursement for approved and unapproved uses. For lidocaine patch, we subcategorized approved prescriptions into two subtypes of unapproved uses: neuropathic pain, for which some evidence of efficacy exists, and non-neuropathic pain. Results: We found that prescriptions for lidocaine patch, modafinil, and cinacalcet associated with non-orphan diagnoses rose at substantially higher rates (average monthly increases in number of patients of 14.6, 1.45, and 1.58) than prescriptions associated with their orphan diagnoses (3.12, 0.24, and 0.03, respectively (p<0.001 for all)). By contrast, for imatinib, approved uses increased significantly over off-label (0.97 vs. 0.47 patients, p<0.001). Spending on off-label uses was highest for lidocaine patch and modafinil (>75%). Increases in lidocaine patch use for non-neuropathic pain far exceeded neuropathic pain (10.2 vs. 3.6 patients, p<0.001). Discussion In our sample, three of four top-selling orphan drugs were used more commonly for non-orphan indications. These orphan drugs treated common clinical symptoms (pain and fatigue) or laboratory abnormalities. We should continue to monitor orphan drug use after approval to identify products that come to be widely used for non-FDA approved indications, particularly those without adequate evidence of efficacy.
Published Version: doi:10.1371/journal.pone.0031894
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3283698/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:8623550

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters